urinary retention four weeks following her second dose; saddle anesthesia four weeks following her second dose; leg weakness four weeks following her second dose; She continues to have gait imbalance and urinary incontinence; urinary incontinence; This is a literature report.  A 59-year-old female patient received COVID-19 Vaccine - Manufacturer Unknown, as dose 2, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Covid-19 vaccine (DOSE 1; MANUFACTURER UNKNOWN), for COVID-19 Immunization. The following information was reported: URINARY RETENTION (medically significant), 4 weeks after the suspect product(s) administration, outcome "unknown", described as "urinary retention four weeks following her second dose"; ANAESTHESIA (medically significant), 4 weeks after the suspect product(s) administration, outcome "unknown", described as "saddle anesthesia four weeks following her second dose"; MUSCULAR WEAKNESS (medically significant), 4 weeks after the suspect product(s) administration, outcome "unknown", described as "leg weakness four weeks following her second dose"; GAIT DISTURBANCE (non-serious), 4 weeks after the suspect product(s) administration, outcome "unknown", described as "She continues to have gait imbalance and urinary incontinence"; URINARY INCONTINENCE (non-serious), outcome "unknown". The patient underwent the following laboratory tests and procedures: CSF test: compatible with neuroinflammation; Magnetic resonance imaging: demonstrated patchy T2 hyperintensities throughout, notes: the pons, C- and T-spine. Clinical course: A healthy female developed urinary retention, saddle anesthesia and leg weakness four weeks following her second dose. MRI spine demonstrated patchy T2 hyperintensities throughout the pons, C- and T-spine. She continues to have gait imbalance and urinary incontinence. Other causes of transverse myelitis including neuromyelitis optica and myelin oligodendrocyte associated disease were ruled out in Case 1, 2 and 4. CSF analysis in all were compatible with neuro-inflammation. Conclusion: These cases raise concern that mRNA vaccinations may be associated with neurologic complications due to heightened immune reactivity. Further studies are needed to understand the risk associated with mRNA vaccinations.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.; Sender's Comments: Based on the information in the case report and a plausible temporal relationship, a possible causal association between the events and suspect drug BNT162B2 cannot be excluded. The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to regulatory authorities, Ethics Committees, and Investigators, as appropriate.,Linked Report(s) : US-PFIZER INC-PV202200110398 Same Article/drug/event and different patient;